pdf   xlsx method abbreviations

lung cancer : non small cell (NSCLC), gene alteration target therapy versus platinum association, meta-analysis of study results

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths (OS) 0.87 [0.64, 1.18]< 10%1 study (1/-)81.5 %NAnot evaluable crucial-
progression or deaths (PFS) 0.30 [0.22, 0.40]< 10%1 study (1/-)100.0 %NAnot evaluable important-
DCR 3.85 [2.18, 6.82]> 10%1 study (1/-)100.0 %NAnot evaluable non important-
objective responses (ORR) 5.39 [3.45, 8.43]> 10%1 study (1/-)100.0 %NAnot evaluable non important-

safety endpoints 00

AE (any grade) 0.34 [0.04, 2.83]< 10%1 study (1/-)84.0 %NAnot evaluable non important-
AE (grade 3-4) 0.31 [0.20, 0.48]< 10%1 study (1/-)100.0 %NAnot evaluable non important-
AE leading to death (grade 5) 1.96 [0.22, 17.74]< 10%1 study (1/-)27.5 %NAnot evaluable non important-
TRAE (any grade) 0.60 [0.32, 1.11]< 10%1 study (1/-)94.9 %NAnot evaluable non important-
TRAE (grade 3-4) 0.12 [0.06, 0.22]< 10%1 study (1/-)100.0 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.